TABLE 1—
Sustained Virological Response, % (n) | χ2 | |
HCV genotype (n) | ||
1 (38) | 47.4 (18) | 13.6, P < .01 |
2 (12) | 100.0 (12) | |
3 (30) | 76.7 (23) | |
Age, y (n) | ||
20–34 (28) | 75.0 (21) | 2.2, P = .331 |
35–49 (42) | 64.3 (27) | |
50–64 (10) | 50.0 (5) | |
Methadone maintenance treatment (n) | ||
Yes (26) | 80.8 (21) | 3.6, P = .057 |
No (54) | 59.3 (32) | |
HCV risk factors, self-reported (n) | ||
Injection drug use (alone or in combination with other risks) (44) | 77.3 (34) | 7.2, P = .027 |
Noninjection drug use risks (21) | 61.9 (13) | |
Unknown (15) | 40.0 (6) | |
Treatment course (n) | ||
Completed (63) | 79.4 (50) | 23.1, P < .01 |
Not completed or stopped early (17) | 17.6 (3) | |
Overall | 66.3 (53) | |
(95% CI = 56.1%, 77.6%) |
Note. CI = confidence interval.